SEC v. Amit Dagar

Amit Dagar, a former Pfizer Inc. employee, allegedly traded in advance of the company’s November 5, 2021, announcement that a randomized, double-blind study of its COVID-19 antiviral treatment, Paxlovid, was successful, according to the SEC. Dagar's trading allegedly generated approximately $214,395 in illicit profits, according to the SEC. Atul Bhiwapurkar, Dagar's friend and business partner, also allegedly traded in advance of the announcement and allegedly generated approximately $60,300 in illicit profits, according to the SEC.

Summary generated from official Securities and Exchange Commission press release